Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Evaluation of efficacy of treatment with epirubicin (5 years follow-up). Evaluation of
frequency of dose reduction. Evaluation of frequency of neoadjuvant treatment with E(120mg) /
C(600mg). Evaluation of unexpected and serious adverse events.
(E=Epirubicin; C =Cyclophosphamide)